Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001650664-25-000156
Filing Date
2025-11-10
Accepted
2025-11-10 16:05:33
Documents
71
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q edit-20250930.htm   iXBRL 10-Q 1050053
2 EX-31.1 edit-20250930xex311.htm EX-31.1 9649
3 EX-31.2 edit-20250930xex312.htm EX-31.2 9619
4 EX-32.1 edit-20250930xex321.htm EX-32.1 6221
  Complete submission text file 0001650664-25-000156.txt   5768415

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT edit-20250930.xsd EX-101.SCH 37893
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT edit-20250930_cal.xml EX-101.CAL 60430
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT edit-20250930_def.xml EX-101.DEF 181267
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT edit-20250930_lab.xml EX-101.LAB 562955
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT edit-20250930_pre.xml EX-101.PRE 383190
74 EXTRACTED XBRL INSTANCE DOCUMENT edit-20250930_htm.xml XML 735767
Mailing Address 11 HURLEY ST. CAMBRIDGE MA 02141
Business Address 11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Editas Medicine, Inc. (Filer) CIK: 0001650664 (see all company filings)

EIN.: 464097528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37687 | Film No.: 251466136
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)